Evidence map›Paper›PMID 36969239›Full record

ArticleFrontiers in immunology2023

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.

Brandon Carter, Pinghan Huang, Ge Liu, Yuejin Liang, Paulo J C Lin, Bi-Hung Peng, Lindsay G A McKay, Alexander Dimitrakakis, Jason Hsu, Vivian Tat and 9 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Pan-Variant SARS-CoV-2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Brandon CarterComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.
Pinghan HuangDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.
Ge LiuComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.
Yuejin LiangDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.
Paulo J C LinAcuitas Therapeutics, Vancouver, BC, Canada.
Bi-Hung PengDepartment of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.
Lindsay G A McKayNational Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.
Alexander DimitrakakisComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.
Jason HsuDepartment of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.
Vivian TatDepartment of Pathology, The University of Texas Medical Branch, Galveston, TX, United States.
Panatda Saenkham-HuntsingerDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.
Jinjin ChenDepartment of Biomedical Engineering, Tufts University, Medford, MA, United States.
Clarety KasekeRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Gaurav D GaihaRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Qiaobing XuDepartment of Biomedical Engineering, Tufts University, Medford, MA, United States.
Anthony GriffithsNational Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.
Ying K TamAcuitas Therapeutics, Vancouver, BC, Canada.
Chien-Te K TsengDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.
David K GiffordComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.
The University of Texas Medical Branch at Galveston · USMassachusetts Institute of Technology · USAcuitas Therapeutics (Canada) · CABoston University · USRagon Institute of MGH, MIT and Harvard · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine has not been shown to provide effective anti-SARS-CoV-2 prophylaxis. Here we show a mRNA-LNP vaccine (MIT-T-COVID) based on highly conserved short peptide epitopes activates CD8

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, NeutralizingCD8-Positive T-LymphocytesCOVID-19 VaccinesEpitopesHumansMiceMice, TransgenicPost-Acute COVID-19 SyndromeRNA, MessengerSpike Glycoprotein, CoronavirusAntibodies, NeutralizingCOVID-19 VaccinesEpitopesRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2challenge studyCOVID-19mRNA-LNPpeptide vaccineSARS-CoV-2T cell vaccine

Identifiers

PMID36969239
PMCPMC10033589
OpenAlexW4323666610

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read53
identifiers read4
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.